TumorDiagnostik & Therapie 2004; 25(4): 192-196
DOI: 10.1055/s-2004-813484
Symposium Report

© Georg Thieme Verlag KG Stuttgart · New York

Pharmakokinetik von Imatinib (STI571) und seinem Hauptmetaboliten N-Desmethyl-Imatinib

Pharmacokinetics of Imatinib and its Main Metabolite N-desmethyl-imatinibE. Schleyer1 , O.-G Ottmann2 , T. Illmer1 , S. Pursche1 , T. Leopold1 , M. Bonin1 , J. Freiberg-Richter1 , A. Jenke1 , U. Platzbecker1 , M. Bornhäuser1 , G. Ehninger1 , P. le Coutre3
  • 1Universitätsklinik Carl Gustav Carus Dresden
  • 2Klinikum der Wolfgang Goethe Universität Frankfurt
  • 3Medizinische Klinik m. S. Hämatologie und Onkologie, Virchow Campus, Charité Humboldt Universität Berlin
Further Information

Publication History

Publication Date:
23 August 2004 (online)

Literatur

  • 1 Druker B J, Talpaz M, Resta D J. et al . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.  N Engl J Med. 2001;  344 1031-1037
  • 2 Kantarjian H M, O’Brien S, Cortes J E. et al . Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.  Clinical Cancer Research. 2002;  8 2167-2176
  • 3 Sawyers C L, Hochhaus A, Feldman E. et al . A phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia positive chronic myeloid leukemia in myeloid blast crisis.  Blood. 2000;  96 503 a
  • 4 Hochhaus A, Kantarijan H M, Sawyers C L. et al . Glivec® (Imatinib Mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloic leukemia in late chronic phase: results of a phase II study.  Hematol. 2001;  J 1 (Suppl) 199
  • 5 Druker B J, Sawyers C L, Kantarjian H. et al . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.  N Engl J Med. 2001;  344 (14) 1038-1042
  • 6 Ottmann O G, Sawyers C L, Druker B. et al . Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukemias.  Hematol. 2001;  J 1 (Suppl) 93
  • 7 le C outre P, Tassi E, Varella-Garcia M. et al . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.  Blood. 2000;  95 1758-1766
  • 8 Bakhtiar R, Lohne J, Ramos L. et al . High-throughput quantification of the anti-leukemia drug STI571 (GleevecE) and its main metabolite (CGP 74 588) in human plasma using liquid chromatography-tandem mass spectrometry.  Journal of Chromatography B. 2002;  768 325-340
  • 9 Heinzel G, Hammer R, Wolf M. et al . Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models.  Arzneimittelforschung. 1977;  27 904
  • 10 Peng B, Dutreix C, Mehring G. et al . Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.  J Clin Pharmacol. 2004;  44 158

PD Dr. med. Eberhard Schleyer

Medizinische Klinik und Poliklinik I an der Technischen Universität Dresden

Fetscherstr. 48

01307 Dresden

Phone: ++ 49/3 51/4 58-45 15

Fax: ++49/3 51/4 58-53 62

Email: schleyer@mk1.med.tu-dresden.de

    >